Products Affected - Description

• • Camptosar intravenous solution for injection, Pfizer, 20 mg/mL, 15 mL vial, NDC 00009-0082-02
  • Camptosar intravenous solution for injection, Pfizer, 20 mg/mL, 2 mL vial, NDC 00009-7529-10
  • Camptosar intravenous solution for injection, Pfizer, 20 mg/mL, 5 mL vial, NDC 00009-0112-05
  • Irinotecan hydrochloride intravenous solution for injection, Eugia US, 20 mg/mL, 15 mL vial, NDC 55150-0354-01
  • Irinotecan hydrochloride intravenous solution for injection, Eugia US, 20 mg/mL, 2 mL vial, NDC 55150-0352-01
  • Irinotecan hydrochloride intravenous solution for injection, Pfizer, 20 mg/mL, 2 mL vial, NDC 61703-0349-16
  • Irinotecan hydrochloride intravenous solution for injection, Pfizer, 20 mg/mL, 25 mL vial, NDC 61703-0349-36
  • Irinotecan hydrochloride intravenous solution for injection, Pfizer, 20 mg/mL, 5 mL vial, NDC 61703-0349-09
  • Irinotecan hydrochloride intravenous solution for injection, Sagent, 20 mg/mL, 2 mL vial, NDC 25021-0230-02
  • Irinotecan hydrochloride intravenous solution for injection, Sagent, 20 mg/mL, 5 mL vial, NDC 25021-0230-05

Reason for the Shortage

• • Apotex has irinotecan injection available.
  • Eugia did not provide a reason for the shortage.
  • Hikma has irinotecan injection available.
  • Pfizer has irinotecan injection on shortage due to manufacturing delays. In mid-2026, heavy rains flooded a key manufacturing facility in Gujarat, India.
  • Sagent did not provide a reason for the shortage.

Available Products

• • Irinotecan hydrochloride intravenous solution for injection, Apotex, 20 mg/mL, 2 mL vial, NDC 60505-6128-00
  • Irinotecan hydrochloride intravenous solution for injection, Apotex, 20 mg/mL, 5 mL vial, NDC 60505-6128-01
  • Irinotecan hydrochloride intravenous solution for injection, Eugia US, 20 mg/mL, 5 mL vial, NDC 55150-0353-01
  • Irinotecan hydrochloride intravenous solution for injection, Hikma, 20 mg/mL, 2 mL vial, NDC 00143-9702-01
  • Irinotecan hydrochloride intravenous solution for injection, Hikma, 20 mg/mL, 5 mL vial, NDC 00143-9701-01

• • Eugia has irinotecan 20 mg/mL 2 mL and 15 mL vials on intermittent back order and the company is releasing supplies as they become available.
  • Pfizer has irinotecan 20 mg/mL 2 mL vials in limited supply and the company estimates supply with be depleted before the end of the year. The 20 mg/mL 5 mL and 25 mL vials are also in limited supply and the company estimates supply will be depleted in 1st quarter 2027. Once supply is depleted, product is not expected to be available throughout 2027.
  • Pfizer has Camptosar 20 mg/mL 2 mL and 5 mL vials in limited supply and the company estimates supply will be depleted in 1st quarter 2027. Camptosar 20 mg/mL 15 mL vials are also in limited supply and the company estimates supply with be depleted before the end of the year. Once supply is depleted, product is not expected to be available throughout 2027.
  • Sagent has irinotecan 20 mg/mL 2 mL and 5 mL vials on back order and the company cannot estimate a release date.

• • Consider evaluating the health-care system's total supply of irinotecan before beginning patients on combination chemotherapy regimens containing irinotecan. If adequate supplies are not available, select an alternative regimen.
  • The choice of an alternative agent must be patient-specific and based on renal function, liver function, and the neoplasm type and location. No single agent can be substituted for irinotecan.
  • Consult a Hematology/Oncology specialist for patient- and neoplasm-specific recommendations.
  • Refer to the ASHP Infographics on Drug Product Shortages for more guidance on developing a multidisciplinary plan when the supply must be allocated. https://www.ashp.org/-/media/assets/drug-shortages/docs/ASHP-drug-shortages-infographic.pdf?rev=8c909ada5cfb4f05a28d5452eb57dd16
  • Refer to national guidelines such as those from the National Comprehensive Cancer Network (www.nccn.org) or American Society of Clinical Oncology (http://www.asco.org/) for additional information regarding therapeutic use.